Transgene Sa Stock Market Capitalization
| TNG Stock | EUR 0.73 0.02 2.82% |
Transgene SA fundamentals help investors to digest information that contributes to Transgene's financial success or failures. It also enables traders to predict the movement of Transgene Stock. The fundamental analysis module provides a way to measure Transgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transgene stock.
Transgene |
Transgene SA Company Market Capitalization Analysis
Transgene's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Transgene Market Capitalization | 205.42 M |
Most of Transgene's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transgene SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Transgene SA is about 205.42 M. This is 98.41% lower than that of the Healthcare sector and 95.67% lower than that of the Biotechnology industry. The market capitalization for all France stocks is 98.92% higher than that of the company.
Transgene Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transgene's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics of similar companies.Transgene is currently under evaluation in market capitalization category among its peers.
Transgene Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 144.73 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | 18.08 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 10.07 X | |||
| Revenue | 9.99 M | |||
| Gross Profit | (15.87 M) | |||
| EBITDA | (16.55 M) | |||
| Net Income | (19.54 M) | |||
| Cash And Equivalents | 16.9 M | |||
| Cash Per Share | 0.27 X | |||
| Debt To Equity | 162.30 % | |||
| Current Ratio | 1.52 X | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Target Price | 4.3 | |||
| Number Of Employees | 143 | |||
| Beta | 0.79 | |||
| Market Capitalization | 205.42 M | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (538 M) | |||
| Working Capital | 24 M | |||
| Current Asset | 51 M | |||
| Current Liabilities | 27 M | |||
| Z Score | -7.0 | |||
| Net Asset | 101.84 M |
About Transgene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transgene SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Transgene Stock
Transgene financial ratios help investors to determine whether Transgene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.